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We assessed the possibility of intrahepatic inoculation with a plasmid encoding hepatitis C virus (HCV) proteins to elicit
HCV-specific cytotoxic T lymphocytes (CTL) in mice as a conventional animal model of HCV infection. BALB/c mice were
intrahepatically or intramuscularly inoculated with an expression plasmid DNA encoding HCV structural proteins under the
control of the elongation factor 1-a promoter. Expressions of HCV-core protein and envelope proteins (E1 and E2) in
hepatocytes were detected immunohistochemically 6 days after inoculation. CTL responses were examined using target
cells either pulsed with a specific peptide or infected with a recombinant vaccinia virus expressing HCV structural protein.
Both intrahepatically and intramuscularly DNA-inoculated mice developed CD81, MHC class I-restricted CTL responses that
recognized the peptide pulsed as well as HCV proteins expressing target cells. These studies demonstrated the usefulness
of a murine model of HCV infection induced by direct intrahepatic DNA inoculation for understanding the immunopathogenic
mechanisms in HCV infection. © 2000 Academic Press
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Hepatitis C virus (HCV) is one of the major agents of
chronic hepatitis and liver disease worldwide (Choo et
al., 1989; Houghton et al., 1991; Kuo et al., 1989).
Infection with HCV leads to chronic hepatitis in more
than 50% of cases, and some of these cases progress
to cirrhosis and perhaps hepatocellular carcinoma
(Saito et al., 1990). While the pathogenic mechanism of
progression of hepatitis caused by HCV has not yet
been clearly elucidated, much information has accu-
mulated showing that virus-specific cytotoxic T lym-
phocytes (CTL) play a critical role in the host cellular
immune response against HCV (Imawari et al., 1989;
Rehermann et al., 1996). CTL might contribute to hep-
atocellular damage in HCV infection during the course
of killing virus-infected cells. Thus, identification of
immunodominant epitopes that elicit antiviral CTL
might contribute to an understanding of the pathogen-
esis of HCV infection.
An animal model for HCV infection is required both for
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120vaccine development and for understanding the patho-
genesis of HCV infection. Although the chimpanzee is
the only known animal model of HCV infection, chimpan-
zees are difficult to acquire as laboratory animals. HCV
and HLA transgenic mice have therefore been employed
for vaccine development and for examination of HCV
pathogenesis (Koike et al., 1995; Matsuda et al., 1998;
Moriya et al., 1995; Pasquinelli et al., 1995; Shirai et al.,
1995). Recently, it was reported that HCV core transgenic
mice that had hepatic steatosis early in life developed
hepatic tumors after the age of 16 months (Moriya et al.,
1997). These reports suggest that the mouse system
might be useful as an animal model for exploring a novel
approach to understanding the pathogenesis of HCV
infection. HCV transgenic mice, however, cannot be used
to assess obvious immune responses against HCV an-
tigens because of the expression of inserted HCV gene
products recognized as endogenous autologous anti-
gens. Thus, animal models showing immune responses
are required for studying the pathogenesis of HCV infec-
tion. In the present study, we established a novel animal
model of HCV infection by a single intrahepatic immuni-
zation with plasmid DNA encoding HCV structural pro-
teins, and we assessed the usefulness of the induction
of HCV-specific CTL for understanding the pathogenesis
of HCV infection by HCV-specific immune responses.
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nduction of HCV-specific cytotoxic activities by a
ingle intramuscular immunization with plasmid DNA
ontaining the elongation factor 1-a (EF1-a) promoter
To confirm the induction of HCV-specific effector cells
y intramuscular immunization of the pEFCE1E2 plas-
id, spleen cells obtained from one-shot DNA-immu-
ized mice were assessed for their ability to lyse core,
1 peptide-pulsed, recombinant vaccinia virus (rVV)-HCV
2-infected MHC-matched target cells. The pEFCE1E2-
mmunized mice generated HCV-specific effector re-
ponses even after a single immunization (Fig. 1). The
EFCE1E2 immunization of mice generated effector cell
esponses capable of recognizing not only peptide
pitopes (Figs. 1a and 1b) but also endogenously pro-
essed viral proteins (Fig. 1c). Those effector cells were
D81, MHC class I-restricted CTL (data not shown), and
hese results were in accordance with those obtained in
FIG. 1. Spleen cells from mice intramuscularly immunized with
EFCE1E2 develop HCV-specific lytic activities. Cytolytic activities
gainst core (a) and E1 (b) were assessed using CTL epitope
eptide-labeled (Bruna-Romero et al., 1997; Saito et al., 1990) target
cells. Target cells infected with rVV-HCV E2 were used for measur-
ing cytotoxic activities against E2 (c). Open symbols indicate the
lysis of target cells labeled with the CTL epitope peptide (HCV core
or E1) or infected with rVV-HCV E2, and closed symbols indicate the
lysis of control peptide-labeled or control rVV-infected target cells.
The data represent the mean percentage of the specific lysis values
obtained from five mice.ur previous study (Nishimura et al., 1999).CV structural proteins are expressed in liver cells in
ice intrahepatically immunized with pEFCE1E2
To avoid the influence of injection damage, we used
EFCE1E2, which can induce immune responses with only
single immunization (Nishimura et al., 1999). In fact, no
athological changes were detected in control sections
hat had been administered a single injection of the control
lasmid. Immunohistochemical examination of the livers of
ice intrahepatically immunized with pEFCE1E2 was per-
ormed 6 days to 16 weeks after inoculation with the plas-
id. HCV structural proteins were observed in hepatocytes
Figs. 2a, 2b, and 2c) and other cells in mouse liver (e.g.,
ndothelial cells; data not shown). These HCV structural
roteins were observed for 16 weeks after injection, and a
ositive border was clearly observed only in the electropo-
ated area. These HCV structural protein-expressing cells
ere observed in 2 to 7% of hepatocytes in injected liver,
nd there was no tendency to changes in expression rate
f HCV structural proteins and or upon histological exami-
ation in the observation period. Moreover, there was no
ignificant pathological abnormality in other organs. Based
n these findings, injected plasmid DNA was inserted into
he cells only in the area in which electric pulses had been
dministered. During the observation period, the only
athologic change detected in the livers of mice inoculated
ith pEFCE1E2 was mild inflammation (Fig. 2e), and no
athological changes were detected in the livers inoculated
ith the control plasmid (Fig. 2f).
CV-specific effector cells are elicited in mice
ntrahepatically immunized with the plasmid
Spleen cells obtained from mice intrahepatically immu-
ized with pEFCE1E2 were assessed for lytic activities
gainst rVV-HCV core- or rVV-HCV E1-infected target cells.
ice intrahepatically immunized with pEFCE1E2 generated
CV-core- and HCV-E1-specific effector cells 2 weeks after
noculation (Figs. 3a and 3b). Moreover, these effector cells
lso lysed target cells labeled with HCV-core or -E1 CTL
pitope peptides (Figs. 3c and 3d). However, no such ef-
ector cells were observed in the spleens of mice intrahe-
atically immunized with the control plasmid. Thus, intra-
epatic immunization with pEFCE1E2 induces the genera-
ion of effector cells that recognize not only HCV structural
roteins endogenously processed by target cells but also
TL epitope peptide-labeled target cells. HCV structural
rotein-specific antibody responses were not detected by
mmunofluorescence analyses until 6 weeks after injection
data not shown).
EFCE1E2 intrahepatic immunization induces the
eneration of CD81 effector cellsHCV-core and -E1 CTL epitope peptide-specific effec-
tor cells in mice immunized with pEFCE1E2 were cul-
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122 KAMEI ET AL.tured in medium containing anti-CD4 or anti-CD8 mono-
clonal antibodies (mAbs) during a 51Cr release assay.
Anti-CD8 mAbs inhibited cytolysis against target cells
pulsed with HCV-core and -E1 peptides, whereas anti-
CD4 mAbs did not affect effector cell function (Fig. 4).
These results indicated that effector cells expressed
CD8 and used this molecule to lyse the target cells.
Effector cells from mice intrahepatically immunized
with pEFCE1E2 show MHC class I restriction
Lytic activities of HCV-core CTL epitope peptide-spe-
cific effector cells against MHC-matched or -mismatched
target cells labeled with HCV-core and -E1 CTL epitope
peptides were assessed. These peptide-specific effector
cells lysed MHC-matched H-2d target cells but not mis-
matched H-2b target cells pulsed with CTL epitope pep-
FIG. 2. Immunostaining of serial sections of liver tissue from a mo
roteins were observed in hepatocytes. The same cells expressed HCV
E staining of sections of liver tissue from mice after intrahepatic inocu
noculation with control plasmid (f). Bar represents 50 mm.ides (Fig. 5a). Moreover, the functions of these HCV-core
nd -E1 specific effector cells were inhibited by anti-H-Dd and H-2Ld mAbs, respectively, but not by an antibody
o H-2Kd (Fig. 5b). These results indicated that intrahe-
atic pEFCE1E2 immunization elicited CD81 and MHC
class I-restricted CTL and suggested that mice could be
used as a model of HCV infection.
DISCUSSION
Studies of the pathogenesis and the prognosis of HCV
infection have been hampered by the lack of small and
conventional experimental animals that support replica-
tion of HCV. The chimpanzee is the only animal exhibiting
susceptibility to HCV infection and has been used for
studies on the replication of and the immune response
against HCV (Erickson et al., 1993; Farci et al., 1992,
1999). Recently, full-length RNA transcripts from com-
plete cDNA clones of HCV were shown to be infectious
weeks after intrahepatic inoculation with pEFCE1E2. HCV structural
a), -E1 (b), and -E2 (c) proteins (arrows). (d) Control to immunostaining.
ith pEFCE1E2 indicated mild inflammation (e) but not after intrahepaticuse 2
-core (to chimpanzees by intrahepatic injection (Kolikhalov et
al., 1997). Although the chimpanzee is an ideal experi-
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123HCV-SPECIFIC CTL BY INTRAHEPATIC INJECTION OF DNAmental model for HCV infection, chimpanzees are diffi-
cult to obtain for laboratory experiments. Thus, models
using laboratory animals that are easy to obtain are
FIG. 3. Spleen cells from mice intrahepatically inoculated with plas-
mid DNA develop HCV-specific lytic activities. Cytolytic activities
against core (a) and E1 (b) were assessed using target cells infected
with rVV-HCV core and rVV-HCV E1, respectively. These effector cells
also lysed target cells labeled with the CTL epitope peptide of HCV
core (c) and E1 (d). Open symbols indicate the lysis of target cells
infected with rVV-HCV core or rVV-HCV E1 or labeled with CTL epitope
peptide (HCV core or E1), and closed symbols indicate the lysis of
control peptide-labeled or control rVV-infected target cells. The data
represent the mean percentage of the specific lysis values obtained
from five mice.
FIG. 4. HCV-specific lysis by intrahepatic pEFCE1E2 inoculation is m
EFCE1E2 were stimulated with CTL epitope peptide, and lytic activi
nti-CD4 mAbs or anti-CD8 mAbs. The effector:target ratio was 80:1. The data
rom five mice.needed in order to understand the effects of HCV infec-
tions. To overcome this difficulty, various types of HCV
transgenic mice bearing HCV cDNA have been estab-
lished for investigating the mechanisms of hepatitis and
tumorigenicity induced by HCV infection (Kawamura et
al., 1997; Koike et al., 1995; Matsuda et al., 1998; Moriya
t al., 1995, 1997; Pasquinelli et al., 1995). Transgenic
ice may be a good model system for elucidating the
oles of these proteins in the pathogenesis of hepatitis or
epatic tumorigenesis; however, transgenic mice do not
rovide a perfect system for understanding the patho-
enesis of HCV infection. First, HCV gene products ex-
ress not only the original target organ but also other
ontarget cells. To overcome this problem, a liver-spe-
ific expression promoter has been used in some cases
Kawamura et al., 1997; Matsuda et al., 1998; Moriya et
l., 1995; Pasquinelli et al., 1995). Second, it is difficult to
stablish transgenic mouse lines in some cases. Most
ransgenic mice expressing full-length HCV DNA have
ied after breeding, and breeding lines of female mice
xpressing HCV-core DNA have been difficult to main-
ain (Matsuda et al., 1998; Moriya et al., 1997). Finally,
mmune responses in models of HCV infection are very
mportant for understanding the pathogenesis of HCV
nfection; however, immune responses against exoge-
ous transgene products in transgenic mice are difficult
o detect in most cases because exogenous gene prod-
cts are probably recognized as endogenous antigens.
ecently, excellent transgenic mouse lines with clear
mmune responses against HCV gene products have
een established by using a Cre/loxP system (Wakita et
l., 1998). The HCV antigens are not expressed without
dministration of an adenovirus that expresses Cre DNA
ecombinase. This transgenic mouse line showed overt
mmune responses that were correlated with the status
f hepatitis. This model might be useful for understand-
by CD81 cells. Spleen cells from mice intrahepatically inoculated with
ainst peptide-labeled target cells were assessed in the presence ofediated
ties agrepresent the mean percentage of the specific lysis values obtained
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124 KAMEI ET AL.ing the correlation between immune responses and hep-
atitis if there is no influence of adenovirus infection in the
model.
Direct gene transfer into liver cells by in vivo electro-
poration has been reported to be a useful method for
expressing antigens (Suzuki et al., 1998). In the present
study, we showed the expression of HCV antigens in
mice intrahepatically inoculated with plasmid having the
HCV structural protein gene. There were some differ-
ences in the pathological features of the livers of these
FIG. 5. HCV-specific lysis was restricted by MHC class I. (a) HCV-
core or HCV-E1 CTL epitope peptides stimulated spleen cells from
mice intrahepatically immunized with pEFCE1E2 lysed HCV-core or
HCV-E1 CTL epitope peptide-pulsed H-2d but not H-2b target cells.
Effector cells were examined for their lytic activities against HCV-core
or HCV-E1 CTL epitope peptide-pulsed H-2b or H-2d target cells. (b)
HCV-core or HCV-E1 CTL epitope-specific lytic activities were inhibited
by anti-H-2Dd or anti-H-2Ld mAb, respectively. Effector cells were as-
sessed for HCV-core or HCV-E1 CTL epitope-specific lytic activities in
the presence of anti-H-2Kd, anti-H-2Dd, or anti-H-2Ld mAb. Closed and
hatched bars indicate the lysis of target cells labeled with HCV-core or
HCV-E1 CTL epitope peptide, and open bars indicate the lysis of
control peptide-labeled target cells. The effector:target ratio was 80:1.
The data represent the mean percentage of the specific lysis values
obtained from five mice.mice from those of HCV-infected humans. Our model
showed the expression of HCV antigens not only inhepatocytes but also in other cells (e.g., sinus endothe-
lial cells), unlike that in the liver of HCV-infected humans.
Another difference between our experimental mice and
HCV-infected humans was the extent of hepatitis. Since
electrotransfection efficiency was observed in only a
small area surrounding the electrode needles, mice in-
trahepatically inoculated with HCV genes did not show
any increment in the serum levels of parameters affected
by hepatitis, such as alanine aminotransferase (data not
shown). These characteristics were dependent on the
administration of DNA by using the in vivo electropora-
tion method, and it is thought that there is still room for
improvement in this technique.
Cellular immune responses, particularly those medi-
ated by CD81 CTL, may generally play important roles in
the pathogenesis and control of HCV infection (Nelson et
al., 1997). For the purpose of understanding these roles,
animal models should elicit HCV-specific CTL respons-
es; however, most of the transgenic mouse lines thus far
established have not clearly shown the existence of
HCV-specific CTL. Moreover, the chimpanzee, which has
been used for studies on the replication of and the
immune response against HCV, is difficult to employ for
laboratory experiments. The present study demonstrated
the elicitation of HCV-specific CD81, MHC class I-re-
tricted CTL in mice intrahepatically inoculated with HCV
NA. The contribution of such CTL to the pathogenesis
f HCV infection can now be assessed in an intrahepati-
ally immunized mouse model.
MATERIALS AND METHODS
lasmid
The HCV genotype 1b cDNA was isolated from a
apanese individual with chronic hepatitis C by the
ethod previously described (Wakita and Wands, 1994).
he cDNA was ligated into pEF321-Neo (Kim et al., 1993).
he plasmid pEFCE1E2 encoding structural proteins,
ore protein, and E1 and E2 proteins (amino acids 1–705)
f type 1b HCV under the control of the EF1-a promoter
(Nelson et al., 1997) was used for immunization (Fig. 6).
Plasmid DNA was amplified in Escherichia coli and was
purified using a Qiagen purification kit (Qiagen, Inc., CA).
It has been reported that a single intramuscular immu-
nization with pEFCE1E2 elicits HCV-specific CTL (Nish-
imura et al., 1999). An empty plasmid, pEF321-Neo, was
used as a control.
Immunization
Six- to eight-week-old BALB/c mice were given a sin-
gle intramuscular or intrahepatic injection of the plas-
mids (10 mg/mouse), and then an electric pulse was
immediately applied by an Electric Square Porator (T820;
BTX, San Diego, CA). Pulses were delivered to the liver or
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125HCV-SPECIFIC CTL BY INTRAHEPATIC INJECTION OF DNAmuscle using a pair of electrode needles. Eight electric
pulses were administered at a rate of one pulse per
second. Pulses were delivered to the left lobe of the
mouse liver or to the gastrocnemius muscle, which had
been injected between electrode needles separated by a
distance of approximately 5 mm. Electric pulses were
delivered twice to the left lobe of liver. In the second
administration, the axis of the electrode needles was
changed to an angle of 90° to the axis of electrode
needles in the first electric administration. The electric
pulse was 99 ms in duration and the voltage was 50 V.
The resistance was monitored with a graphic pulse an-
alyzer (Optimizer 500, BTX).
Tissue preparation
Tissue samples from the liver were fixed in 4% phos-
phate-buffered paraformaldehyde solution, embedded in
paraffin wax, and cut into serial sections of 4 mm in
thickness for histopathologic and immunohistochemical
examinations. The serial sections for histopathologic ex-
amination were stained with hematoxylin and eosin (HE).
Immunohistochemical analysis
After deparaffinization, sections were microwaved for
10 min in sodium citrate buffer (0.01 M, pH 6.0). The
sections were incubated in 3% H2O2 methanol for 30 min
o quench endogenous peroxidase activity and then
ashed three times for 5 min in 0.05 mol Tris–HCl (pH
.6, with 0.15 M NaCl). The sections were then incubated
FIG. 6. Scheme of the HCV structural protein expression plasmid
pEFCE1E2. HCV-core, -E1, and -E2 regions were inserted under the
EF-1a promoter.ith Block Ace (Dainippon Pharmaceutical Co., Ltd.,
saka, Japan) at 37°C in a moisture chamber for 30 mino prevent nonspecific reactions. Subsequently, the sec-
ions were incubated with the following mAbs (diluted
:100) at 37°C overnight: C515 (anti-HCV-core; Anogen,
ntario, Canada), E1-299 (anti-HCV-E1; Austral Biologi-
als, CA), and E2-917 (anti-HCV-E2; Austral Biologicals).
fter being washed the sections were incubated with a
econdary antibody (diluted 1:1000) (rabbit anti-mouse
gG; ICN Pharmaceuticals, Irvine, CA) and treated with
% avidin–botin complex. They were then reacted with
.05% 3,39-diaminobenzidine tetrachloride to visualize
he bound antibodies.
eneration of CTL effector cells
Effector cells were derived from spleen cells as pre-
ursor CTL. Aliquots of 5 3 106 spleen cells were cocul-
ured with 2.5 3 106 mitomycin C-treated autologous
spleen cells labeled with a peptide (20 mg/ml) or infected
ith a rVV expressing HCV E2 (m.o.i. 5) at 37°C in a CO2
incubator. The effector cells generated were harvested
after 5 days of culture.
Cytotoxicity assay
The target cells were MHC-matched (P815) or -mis-
matched (MBL-2 and FBL-3) tumor cells incubated at
37°C under a 5% CO2 atmosphere with the HCV-core
TL epitope (HCV core 133–142, LMGYIPLVGA) (Saito et
l., 1990), HCV-E1 CTL epitope (HCV E1 315–322, GHR-
AWDM) (Bruna-Romero et al., 1997), control peptide
human immunodeficiency virus residues 308–322;
IQRGPGRAFVTIGK) at 10 mg/ml, or rVV expressing HCV
E2 or an irrelevant virus gene (2 3 107 PFU) for 16 h.
Then the target cells were washed and labeled with 51Cr.
The 51Cr-labeled target cells were incubated for 5 h with
effector cells. Spontaneous release varied from 5 to 15%.
Percentage lysis was calculated as [(experimental re-
lease 2 spontaneous release)/(100% release 2 sponta-
eous release)] 3 100. All experiments were performed
ore than three times, and each group consisted of five
ice.
locking of cytolysis
Blocking of cytolysis was performed according to the
ethod reported previously (Van Snick et al., 1982). Ef-
ector cells were preincubated with anti-CD4 mAb
GK1.5) or anti-CD8 mAb (Lyt2.2) at a 1:50 dilution at 4°C
or 1 h, and then the labeled target cells were added.
locking of cytolytic activities by these mAbs was as-
essed by a 5-h 51Cr release assay.
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